M2 Archive: Preview
You haven't logged in. If you have archive credits in your account, please log in now to use them. If not, you can buy credits in our shopping area.
Hemispherx awarded new composition-of-matter patent for current and future ampligen formulations
Pharmaceutical company Hemispherx Biopharma (NYSE MKT:HEB) disclosed on Tuesday the receipt of the US Patent 8,722,874 titled "Double-Stranded Ribonucleic Acids with Rugged Physiochemical Structure and Highly Specific Biologic Activity" from the US Patent Office.
The company added...
If you want to view the full text of this story, you must first purchase archive credits. Return to Archives